Co-loading of Temozolomide with Oleuropein or rutin into polylactic acid core-shell nanofiber webs inhibit glioblastoma cell by controlled release

• Published in: International journal of biological macromolecules 2023-12, Vol.253, p.126722-126722, Article 126722
• Main Authors: Ercelik, Melis, Tekin, Cagla, Parın, Fatma Nur, Mutlu, Busra, Dogan, Hazal Yılmaz, Tezcan, Gulcin, Aksoy, Secil Ak, Gurbuz, Melisa, Yıldırım, Kenan, Bekar, Ahmet, Kocaeli, Hasan, Taskapilioglu, Mevlut Ozgur, Eser, Pınar, Tunca, Berrin
• Format: Article
• Language: English
• Subjects: Combined treatment; Glioblastoma local treatment; Nano-based drug delivery systems
• ISSN: 0141-8130; 1879-0003
• DOI: 10.1016/j.ijbiomac.2023.126722

Glioblastoma (GB) has susceptibility to post-surgical recurrence. Therefore, local treatment methods are required against recurrent GB cells in the post-surgical area. In this study, we developed a nanofiber-based local therapy against GB cells using Oleuropein (OL), and rutin and their combinations with Temozolomide (TMZ). The polylactic acid (PLA) core-shell nanofiber webs were encapsulated with OL (PLAOL), rutin (PLArutin), and TMZ (PLATMZ) by an electrospinning process. A SEM visualized the morphology and the total immersion method determined the release characteristics of PLA webs. Real-time cell tracking analysis for cell growth, dual Acridine Orange/Propidium Iodide staining for cell viability, a scratch wound healing assay for migration capacity, and a sphere formation assay for tumor spheroid aggressiveness were used. All polymeric nanofiber webs had core-shell structures with an average diameter between 133 ± 30.7–139 ± 20.5 nm. All PLA webs promoted apoptotic cell death, suppressed cell migration, and spheres growth (p